Milvexian
Small moleculeexperimental
Clinical trial activity
26 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
21
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02608970)
Timeline
Indications
Studied for
- Acute Coronary Syndrome · Phase 3
- Antithrombins · Phase 1/Phase 2
- Arthroplasty, Replacement, Knee · Phase 2
- Atrial Fibrillation · Phase 3
- Factor XI · Phase 1
- Healthy Volunteers · Phase 1
- Ischemic Attack, Transient · Phase 2
- Ischemic Stroke · Phase 2
- Kidney Failure, Chronic · Phase 1
- Stroke · Phase 3
- Thrombosis · Phase 1
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O- Mol. weight
- 626.46 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4112929 ↗
Also known as
- bms-986177
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05757869 | Phase 3 | Apr 11, 2023 | Bristol-Myers Squibb |
| NCT05754957 | Phase 3 | Apr 7, 2023 | Bristol-Myers Squibb |
| NCT05702034 | Phase 3 | Feb 15, 2023 | Bristol-Myers Squibb |
| NCT05706753 | Phase 1 | Jan 25, 2023 | Bristol-Myers Squibb, Janssen Pharmaceutica NV |
| NCT04965389 | Phase 1 | Jul 16, 2021 | Bristol-Myers Squibb |
| NCT04844424 | Phase 1 | Apr 13, 2021 | Janssen Pharmaceutica NV |
| NCT04569695 | Phase 1 | Dec 14, 2020 | Janssen Pharmaceutica NV |
| NCT04543383 | Phase 1 | Jul 27, 2020 | Janssen Pharmaceutica NV |
| NCT04388501 | Phase 1 | Jul 9, 2020 | Janssen Pharmaceutica NV |
| NCT04448964 | Phase 1 | Jun 26, 2020 | Bristol-Myers Squibb |
| NCT04223349 | Phase 1 | Jan 9, 2020 | Janssen Pharmaceutica NV |
| NCT04206488 | Phase 1 | Dec 20, 2019 | Bristol-Myers Squibb |
| NCT03891524 | Phase 2 | Jun 17, 2019 | Johnson and Johnson |
| NCT03939702 | Phase 1 | May 2, 2019 | Bristol-Myers Squibb |
| NCT03766581 | Phase 2 | Nov 30, 2018 | Bristol-Myers Squibb, Janssen Pharmaceutica NV |
| NCT03698513 | Phase 1 | Oct 4, 2018 | Bristol-Myers Squibb |
| NCT03362437 | Phase 1 | Nov 15, 2017 | Bristol-Myers Squibb |
| NCT03341390 | Phase 1 | Oct 18, 2017 | Bristol-Myers Squibb |
| NCT03196206 | Phase 1 | Jul 1, 2017 | Bristol-Myers Squibb |
| NCT03224260 | Phase 1 | Jun 28, 2017 | Bristol-Myers Squibb |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 20 | 14 | 3 | 2015 |
| Janssen Pharmaceutica NV | For profit | 7 | 6 | 2 | 2018 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1